WP
AMLX icon

Woodline Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Woodline Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2M Buy
846,387
+587
+0.1% +$9.08K 0.05% 438
2026
Q1 		$11.8M Buy
845,800
+392
+0% +$5.51K 0.04% 472
2025
Q4 		$10.2M Buy
845,408
+118
+0% +$1.6K 0.04% 459
2025
Q3 		$11.5M Sell
845,290
-355,000
-30% -$3.34M 0.05% 407
2025
Q2 		$7.69M Sell
1,200,290
-409,157
-25% -$1.99M 0.04% 479
2025
Q1 		$5.7M Buy
+1,609,447
New +$5.73M 0.04% 474
2024
Q3 		– Sell
-523,772
Closed -$995K – 599
2024
Q2 		$995K Hold
523,772
– – 0.01% 463
2024
Q1 		$1.49M Buy
523,772
+52,971
+11% +$693K 0.01% 444
2023
Q4 		$6.93M Sell
470,801
-428,499
-48% -$6.57M 0.08% 272
2023
Q3 		$16.5M Hold
899,300
– – 0.19% 156
2023
Q2 		$19.4M Buy
899,300
+465,100
+107% +$12.6M 0.23% 132
2023
Q1 		$12.7M Sell
434,200
-74,153
-15% -$2.58M 0.17% 170
2022
Q4 		$18.8M Sell
508,353
-512,031
-50% -$18.2M 0.25% 118
2022
Q3 		$28.7M Buy
1,020,384
+630,155
+161% +$15.7M 0.4% 66
2022
Q2 		$7.52M Hold
390,229
– – 0.12% 207
2022
Q1 		$5.01M Buy
+390,229
New +$8.81M 0.08% 244

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Woodline Partners's AMLX Position: Q2 2026 in Review

Woodline Partners increased its Amylyx Pharmaceuticals (AMLX) stake by 0.07% in Q2 2026, buying an estimated $9.08K and bringing the position to 846,387 shares worth $15.2M. The position accounts for 0.05% of the portfolio, ranked #438.

Woodline Partners first reported a position in AMLX in Q1 2022 and has held it in 16 quarters since. The position peaked at $28.7M in Q3 2022. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Woodline Partners held 846,387 shares of Amylyx Pharmaceuticals worth $15.2M as of Q2 2026.
  • Woodline Partners bought 587 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $9.08K.
  • Amylyx Pharmaceuticals made up 0.05% of Woodline Partners's portfolio in Q2 2026, its #438 holding.
  • Woodline Partners first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Woodline Partners's Amylyx Pharmaceuticals position peaked at $28.7M in Q3 2022.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.